RJ
Raymond J. Furey
Executive Vice President, General Counsel and Corporate Secretary
Rigel PharmaceuticalsTherapeutic Areas
Rigel Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TAVALISSE (fostamatinib disodium hexahydrate) | Chronic Immune Thrombocytopenia (ITP) in adults | Approved |
| TAVALISSE | Hospitalized patients with COVID-19 | Emergency Use Authorization |
| REZLIDHIA (olutasidenib) | Relapsed or Refractory Acute Myeloid Leukemia (AML) with susceptible IDH1 mutation | Approved |
| GAVRETO (pralsetinib) | RET-altered cancers (e.g., NSCLC, thyroid cancer) | Approved |
| IRAK1/4 Inhibitor | Lower-Risk Myelodysplastic Syndrome (LR-MDS) | Phase 1b |
| RIPK1 Inhibitor | Immunological Diseases | Preclinical |
Leadership Team at Rigel Pharmaceuticals
RR
Raul R. Rodriguez
President and Chief Executive Officer
DS
Dean Schorno
Executive Vice President and Chief Financial Officer
DA
David A. Santos
Executive Vice President and Chief Commercial Officer
LR
Lisa Rojkjaer
Executive Vice President and Chief Medical Officer
JL
Joseph Lasaga
Executive Vice President and Chief Business Officer
JP
Julie Patel
Senior Vice President, Human Resources
KA
Kamil Ali-Jackson
Member of the Board of Directors
MW
Mark W. Frohlich
Member of the Board of Directors
MP
Michael P. Miller
Member of the Board of Directors (Appointed Feb 2026)